

**ANNUAL ACCOUNTS AND OTHER DOCUMENTS TO BE FILED IN
ACCORDANCE WITH THE BELGIAN COMPANIES AND ASSOCIATIONS
CODE**

IDENTIFICATION DETAILS (at the filing date)NAME: **Galapagos**Legal form ¹: **Public limited company**Address: **Generaal De Wittelaan**N°. **L11 , box A3**Postal code: **2800**Town: **Mechelen**Country: **Belgium**Register of legal persons - commercial court: **Antwerp, division Mechelen**Website ²:E-mail address ²:

Company registration number

0466.460.429DATE **21-03-2023** of filing the most recent document mentioning the date of publication of the deed of incorporation and of the deed of amendment of the articles of association.This filing concerns ³: the ANNUAL ACCOUNTS in**EURO**

approved by the general meeting of

30-04-2024 the OTHER DOCUMENTS

regarding

the financial year covering the period from

01-01-2023

to

31-12-2023

the preceding period of the annual accounts from

01-01-2022

to

31-12-2022The amounts for the preceding period are / are not ⁵ identical to the ones previously published.Total number of pages filed: **57**

Numbers of the sections of the standard model form not filed because they serve no useful purpose: 6.1, 6.2.1, 6.2.4, 6.17, 7, 8, 9, 11, 12, 13, 14, 15

Signature
(name and position)**Stoffels IMC BV, represented by Dr. Paul Stoffels
Chairman of the board of directors**Signature
(name and position)**Jérôme Contamine
Director**¹ Where appropriate, "in liquidation" is stated after the legal form.² Optional mention.³ Tick the appropriate box(es).⁴ If necessary, change to currency in which the amounts are expressed.⁵ Strike out what does not apply.

**LIST OF DIRECTORS, BUSINESS MANAGERS AND AUDITORS AND
DECLARATION REGARDING A COMPLIMENTARY REVIEW OR
CORRECTION ASSIGNMENT****LIST OF DIRECTORS, BUSINESS MANAGERS AND AUDITORS**

COMPLETE LIST with surname, first names, profession, place of residence (address, number, postal code and town) and position within the company

Stoffels IMC BV 0780.918.294

Generaal De Wittelaan L11, box A3, 2800 Mechelen, Belgium

Mandate: Chairman of the board of directors, start: 26-04-2022, end: 28-04-2026

Represented by:

1 Stoffels Paul

Parekh Raj

Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium

Mandate: Director, start: 28-04-2021, end: 10-06-2023

Kerr Mary

Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium

Mandate: Director, start: 28-04-2020, end: 18-09-2023

Guenter Peter

Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium

Mandate: Director, start: 25-04-2023, end: 27-04-2027

O'Day Daniel

Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium

Mandate: Director, start: 25-04-2023, end: 27-04-2027

Higgins Linda

Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium

Mandate: Director, start: 25-04-2023, end: 27-04-2027

Svanberg Elisabeth

Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium

Mandate: Director, start: 28-04-2020, end: 30-04-2024

Baker Dan

Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium

Mandate: Director, start: 26-04-2022, end: 28-04-2026

Contamine Jérôme

Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium

Mandate: Director, start: 26-04-2022, end: 28-04-2026

LIST OF DIRECTORS, BUSINESS MANAGERS AND AUDITORS (continued from previous page)

Schaffert Susanne

Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium

Mandate: Director, start: 12-06-2023, end: 30-04-2028

Sturge Simon

Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium

Mandate: Director, start: 19-09-2023, end: 30-04-2028

BDO Bedrijfsrevisoren BV 0431.088.289

Elsinore Building - Da Vincilaan 9, box E6, 1930 Zaventem, Belgium

Membership number: B00023

Mandate: Auditor, start: 25-04-2023, end: 28-04-2026

Represented by:

1 Lombaerts Ellen

Elsinore Building, Da Vincilaan 9, box E6 1930 Zaventem Belgium

Bedrijfsrevisor, Membership number : A02372

DECLARATION REGARDING A COMPLIMENTARY REVIEW OR CORRECTION ASSIGNMENT

The managing board declares that not a single audit or correction assignment has been given to a person not authorized to do so by law, pursuant to article 5 of the law of 17 March 2019 concerning the professions of accountant and tax advisor.

The annual accounts were / were not * audited or corrected by a certified accountant or by a company auditor who is not the statutory auditor.

If affirmative, should be mentioned hereafter: surname, first names, profession and address of each certified accountant or company auditor and their membership number at their Institute, as well as the nature of their assignment:

- A. Bookkeeping of the company **;
- B. Preparing the annual accounts **;
- C. Auditing the annual accounts and/or
- D. Correcting the annual accounts.

If the tasks mentioned under A or B are executed by accountants or fiscal accountants, the following information can be mentioned hereafter: surname, first names, profession and address of each accountant or fiscal accountant and their membership number at the Institute of Accountants and Tax advisors, as well as the nature of their assignment.

Surname, first names, profession and address	Membership number	Nature of the assignment (A, B, C and/or D)

* Strike out what does not apply.

** Optional mention.

ANNUAL ACCOUNTS

BALANCE SHEET AFTER APPROPRIATION

	Notes	Codes	Period	Preceding period
ASSETS				
FORMATION EXPENSES	6.1	20		
FIXED ASSETS		21/28	342.773.663	287.678.343
Intangible fixed assets	6.2	21	58.349.404	18.165.369
Tangible fixed assets	6.3	22/27	16.024.739	17.595.161
Land and buildings		22	871.570	1.795.864
Plant, machinery and equipment		23	11.668.614	13.524.237
Furniture and vehicles		24	1.231.151	1.761.885
Leasing and other similar rights		25	0	0
Other tangible fixed assets		26	0	0
Assets under construction and advance payments		27	2.253.405	513.176
Financial fixed assets	6.4 / 6.5.1	28	268.399.521	251.917.813
Affiliated Companies	6.15	280/1	249.427.250	247.851.399
Participating interests		280	204.127.249	154.642.558
Amounts receivable		281	45.300.001	93.208.841
Other companies linked by participating interests	6.15	282/3	1	1
Participating interests		282	1	1
Amounts receivable		283		
Other financial fixed assets		284/8	18.972.270	4.066.414
Shares		284	13.965.180	
Amounts receivable and cash guarantees		285/8	5.007.090	4.066.414

	Notes	Codes	Period	Preceding period
CURRENT ASSETS		29/58	<u>3.958.487.436</u>	<u>4.406.769.756</u>
Amounts receivable after more than one year		29	122.091.450	87.847.046
Trade debtors		290	0	0
Other amounts receivable		291	122.091.450	87.847.046
Stocks and contracts in progress		3	73.978.238	52.665.395
Stocks		30/36	73.978.238	52.665.395
Raw materials and consumables		30/31	55.263.353	39.071.496
Work in progress		32	12.598.378	5.790.624
Finished goods		33		
Goods purchased for resale		34	6.116.507	7.803.275
Immovable property intended for sale		35		
Advance payments		36		
Contracts in progress		37		
Amounts receivable within one year		40/41	91.065.773	154.703.979
Trade debtors		40	26.961.771	72.294.845
Other amounts receivable		41	64.104.002	82.409.134
Current investments	6.5.1 / 6.6	50/53	3.576.430.159	3.635.944.614
Own shares		50		
Other investments		51/53	3.576.430.159	3.635.944.614
Cash at bank and in hand		54/58	69.381.431	455.142.600
Accruals and deferred income	6.6	490/1	25.540.385	20.466.121
TOTAL ASSETS		20/58	4.301.261.099	4.694.448.099

	Notes	Codes	Period	Preceding period
EQUITY AND LIABILITIES				
EQUITY		10/15	<u>2.781.701.891</u>	<u>2.508.639.934</u>
Contributions	6.7.1	10/11	3.017.626.375	3.015.856.525
Capital		10	356.444.939	356.111.899
Issued capital		100	356.444.939	356.111.899
Uncalled capital ⁶		101		
Beyond capital		11	2.661.181.436	2.659.744.625
Share premium account		1100/10	2.661.181.436	2.659.744.625
Other		1109/19		
Revaluation surpluses		12		
Reserves		13		
Reserves not available		130/1		
Legal reserve		130		
Reserves not available statutorily		1311		
Purchase of own shares		1312		
Financial support		1313		
Other		1319		
Untaxed reserves		132		
Available reserves		133		
Accumulated profits (losses)	(+)/(-)	14	-235.924.484	-507.216.591
Capital subsidies		15		
Advance to shareholders on the distribution of net assets⁷		19		
PROVISIONS AND DEFERRED TAXES		16	<u>13.972.066</u>	<u>9.751.647</u>
Provisions for liabilities and charges		160/5	13.972.066	9.751.647
Pensions and similar obligations		160		
Taxes		161		
Major repairs and maintenance		162		
Environmental obligations		163		
Other liabilities and charges	6.8	164/5	13.972.066	9.751.647
Deferred taxes		168		

⁶ Amount to be deducted from the issued capital.

⁷ Amount to be deducted from the other components of equity.

	Notes	Codes	Period	Preceding period
AMOUNTS PAYABLE		17/49	<u>1.505.587.142</u>	<u>2.176.056.519</u>
Amounts payable after more than one year	6.9	17		
Financial debts		170/4		
Subordinated loans		170		
Unsubordinated debentures		171		
Leasing and other similar obligations		172		
Credit institutions		173		
Other loans		174		
Trade debts		175		
Suppliers		1750		
Bills of exchange payable		1751		
Advance payments on contracts in progress		176		
Other amounts payable		178/9		
Amounts payable within one year	6.9	42/48	201.874.356	300.241.235
Current portion of amounts payable after more than one year falling due within one year		42		
Financial debts		43		
Credit institutions		430/8		
Other loans		439		
Trade debts		44	129.248.124	67.168.086
Suppliers		440/4	129.248.124	67.168.086
Bills of exchange payable		441		
Advance payments on contracts in progress		46		
Taxes, remuneration and social security	6.9	45	23.757.581	25.642.149
Taxes		450/3	2.310.567	2.045.672
Remuneration and social security		454/9	21.447.014	23.596.477
Other amounts payable		47/48	48.868.651	207.431.000
Accruals and deferred income	6.9	492/3	1.303.712.786	1.875.815.283
TOTAL LIABILITIES		10/49	4.301.261.099	4.694.448.099

⁶ Amount to be deducted from the issued capital.

⁷ Amount to be deducted from the other components of equity.

PROFIT AND LOSS ACCOUNT

	Notes	Codes	Period	Preceding period
Operating income		70/76A	1.004.937.475	785.283.037
Turnover	6.10	70	628.899.063	418.495.174
Stocks of finished goods and work and contracts in progress: increase (decrease)	(+)/(-)	71	6.807.754	4.414.416
Produced fixed assets		72	352.580.235	349.507.630
Other operating income	6.10	74	16.102.765	12.846.816
Non-recurring operating income	6.12	76A	547.659	19.000
Operating charges		60/66A	935.952.364	1.016.944.470
Goods for resale, raw materials and consumables		60	28.718.045	19.860.033
Purchases		600/8	43.223.135	47.750.441
Stocks: decrease (increase)	(+)/(-)	609	-14.505.090	-27.890.408
Services and other goods		61	397.123.712	420.835.395
Remuneration, social security and pensions	(+)/(-) 6.10	62	73.555.658	77.772.120
Amortisations of and other amounts written down on formation expenses, intangible and tangible fixed assets		630	360.512.079	357.368.024
Amounts written down on stocks, contracts in progress and trade debtors: additions (write-backs)	(+)/(-) 6.10	631/4		1.239.142
Provisions for liabilities and charges: appropriations (uses and write-backs)	(+)/(-) 6.10	635/8	4.220.419	866.214
Other operating charges	6.10	640/8	70.785.043	102.149.120
Operating charges reported as assets under restructuring costs	(-)	649		
Non-recurring operating charges	6.12	66A	1.037.409	36.854.421
Operating profit (loss)	(+)/(-)	9901	68.985.111	-231.661.433

	Notes	Codes	Period	Preceding period
Financial income		75/76B	213.501.352	135.553.985
Recurring financial income		75	213.501.352	135.553.985
Income from financial fixed assets		750	109.515.173	10.500.604
Income from current assets		751	101.978.360	22.459.253
Other financial income	6.11	752/9	2.007.818	102.594.128
Non-recurring financial income	6.12	76B		0
Financial charges	6.11	65/66B	37.486.367	60.963.868
Recurring financial charges		65	27.417.452	60.963.868
Debt charges		650	4.053.120	11.085.226
Amounts written down on current assets other than stocks, contracts in progress and trade debtors: additions (write-backs)	(+)/(-)	651	-9.102.765	0
Other financial charges		652/9	32.467.098	49.878.642
Non-recurring financial charges	6.12	66B	10.068.915	0
Profit (Loss) for the period before taxes	(+)/(-)	9903	245.000.095	-157.071.315
Transfer from deferred taxes		780		
Transfer to deferred taxes		680		
Income taxes on the result	(+)/(-) 6.13	67/77	-26.292.013	-19.091.591
Taxes		670/3	72.259	196.797
Adjustment of income taxes and write-back of tax provisions		77	26.364.272	19.288.388
Profit (Loss) of the period	(+)/(-)	9904	271.292.107	-137.979.724
Transfer from untaxed reserves		789		
Transfer to untaxed reserves		689		
Profit (Loss) of the period available for appropriation	(+)/(-)	9905	271.292.107	-137.979.724

APPROPRIATION ACCOUNT

		Codes	Period	Preceding period
Profit (Loss) to be appropriated	(+)/(-)	9906	-235.924.484	-507.216.591
Profit (Loss) of the period available for appropriation	(+)/(-)	(9905)	271.292.107	-137.979.724
Profit (Loss) of the preceding period brought forward	(+)/(-)	14P	-507.216.591	-369.236.867
Transfers from equity		791/2		
from contributions		791		
from reserves		792		
Appropriations to equity		691/2		
to contributions		691		
to legal reserve		6920		
to other reserves		6921		
Profit (loss) to be carried forward	(+)/(-)	(14)	-235.924.484	-507.216.591
Shareholders' contribution in respect of losses		794		
Profit to be distributed		694/7		
Compensation for contributions		694		
Directors or managers		695		
Employees		696		
Other beneficiaries		697		

**RESEARCH COSTS MADE IN A PERIOD THAT STARTED BEFORE
1 JANUARY 2016**

Acquisition value at the end of the period

Movements during the period

Acquisitions, including produced fixed assets

Sales and disposals

Transfers from one heading to another

Acquisition value at the end of the period

Amortisations and amounts written down at the end of the period

Movements during the period

Recorded

Written back

Acquisitions from third parties

Cancelled owing to sales and disposals

Transferred from one heading to another

Amortisations and amounts written down at the end of the period

NET BOOK VALUE AT THE END OF THE PERIOD

Codes	Period	Preceding period
8055P	xxxxxxxxxxxxxxxx	392.970.251
8025		
8035		
(+)/(-) 8045		
8055	392.970.251	
8125P	xxxxxxxxxxxxxxxx	392.970.251
8075		
8085		
8095		
8105		
(+)/(-) 8115		
8125	392.970.251	
81312	<u>0</u>	

RESEARCH COSTS MADE IN A PERIOD THAT STARTED AFTER 31 DECEMBER 2015

Acquisition value at the end of the period

Amortisations and amounts written down at the end of the period

NET BOOK VALUE AT THE END OF THE PERIOD

Codes	Period
8056	2.563.955.263
8126	2.563.955.263
81313	<u>0</u>

CONCESSIONS, PATENTS LICENSES, KNOW-HOW, BRANDS AND SIMILAR RIGHTS

Acquisition value at the end of the period

Movements during the period

Acquisitions, including produced fixed assets

Sales and disposals

Transfers from one heading to another

(+)/(-)

Acquisition value at the end of the period

Amortisations and amounts written down at the end of the period

Movements during the period

Recorded

Written back

Acquisitions from third parties

Cancelled owing to sales and disposals

Transfers from one heading to another

(+)/(-)

Amortisations and amounts written down at the end of the period

NET BOOK VALUE AT THE END OF THE PERIOD

Codes	Period	Preceding period
8052P	xxxxxxxxxxxxxxx	1.253.307.639
8022	397.647.633	
8032	1.081.047	
8042		
8052	1.649.874.224	
8122P	xxxxxxxxxxxxxxx	1.235.142.270
8072	357.463.598	
8082		
8092		
8102	1.081.047	
8112		
8122	1.591.524.821	
211	<u>58.349.404</u>	

ADVANCE PAYMENTS

Acquisition value at the end of the period

Movements during the period

Acquisitions, including produced fixed assets

Sales and disposals

Transfers from one heading to another

Acquisition value at the end of the period

Amortisations and amounts written down at the end of the period

Movements during the period

Recorded

Written back

Acquisitions from third parties

Cancelled owing to sales and disposals

Transferred from one heading to another

Amortisations and amounts written down at the end of the period

NET BOOK VALUE AT THE END OF THE PERIOD

Codes	Period	Preceding period
8054P	xxxxxxxxxxxxxxxx	0
8024		
8034		
(+)/(-) 8044		
8054	0	
8124P	xxxxxxxxxxxxxxxx	
8074		
8084		
8094		
8104		
(+)/(-) 8114		
8124		
213	0	

STATEMENT OF TANGIBLE FIXED ASSETS

	Codes	Period	Preceding period
LAND AND BUILDINGS			
Acquisition value at the end of the period	8191P	xxxxxxxxxxxxxxxx	5.406.558
Movements during the period			
Acquisitions, including produced fixed assets	8161	210.688	
Sales and disposals	8171	166.476	
Transfers from one heading to another	(+)(-) 8181		
Acquisition value at the end of the period	8191	5.450.770	
Revaluation surpluses at the end of the period	8251P	xxxxxxxxxxxxxxxx	
Movements during the period			
Recorded	8211		
Acquisitions from third parties	8221		
Cancelled	8231		
Transferred from one heading to another	(+)(-) 8241		
Revaluation surpluses at the end of the period	8251		
Amortisations and amounts written down at the end of the period	8321P	xxxxxxxxxxxxxxxx	3.610.694
Movements during the period			
Recorded	8271	1.130.928	
Written back	8281		
Acquisitions from third parties	8291		
Cancelled owing to sales and disposals	8301	162.422	
Transferred from one heading to another	(+)(-) 8311		
Amortisations and amounts written down at the end of the period	8321	4.579.201	
NET BOOK VALUE AT THE END OF THE PERIOD	(22)	<u>871.570</u>	

	Codes	Period	Preceding period
PLANT, MACHINERY AND EQUIPMENT			
Acquisition value at the end of the period	8192P	xxxxxxxxxxxxxxxx	27.002.896
Movements during the period			
Acquisitions, including produced fixed assets	8162	548.407	
Sales and disposals	8172	747.916	
Transfers from one heading to another	(+)/(-) 8182		
Acquisition value at the end of the period	8192	26.803.387	
Revaluation surpluses at the end of the period	8252P	xxxxxxxxxxxxxxxx	
Movements during the period			
Recorded	8212		
Acquisitions from third parties	8222		
Cancelled	8232		
Transferred from one heading to another	(+)/(-) 8242		
Revaluation surpluses at the end of the period	8252		
Amortisations and amounts written down at the end of the period	8322P	xxxxxxxxxxxxxxxx	13.478.660
Movements during the period			
Recorded	8272	2.320.135	
Written back	8282		
Acquisitions from third parties	8292		
Cancelled owing to sales and disposals	8302	664.022	
Transferred from one heading to another	(+)/(-) 8312		
Amortisations and amounts written down at the end of the period	8322	15.134.773	
NET BOOK VALUE AT THE END OF THE PERIOD	(23)	<u>11.668.614</u>	

	Codes	Period	Preceding period
FURNITURE AND VEHICLES			
Acquisition value at the end of the period	8193P	xxxxxxxxxxxxxxxx	3.457.445
Movements during the period			
Acquisitions, including produced fixed assets	8163	21.610	
Sales and disposals	8173	240.308	
Transfers from one heading to another	(+)/(-) 8183		
Acquisition value at the end of the period	8193	3.238.747	
Revaluation surpluses at the end of the period	8253P	xxxxxxxxxxxxxxxx	
Movements during the period			
Recorded	8213		
Acquisitions from third parties	8223		
Cancelled	8233		
Transfers from one heading to another	(+)/(-) 8243		
Revaluation surpluses at the end of the period	8253		
Amortisations and amounts written down at the end of the period	8323P	xxxxxxxxxxxxxxxx	1.695.560
Movements during the period			
Recorded	8273	530.079	
Written back	8283		
Acquisitions from third parties	8293		
Cancelled owing to sales and disposals	8303	218.043	
Transfers from one heading to another	(+)/(-) 8313		
Amortisations and amounts written down at the end of the period	8323	2.007.596	
NET BOOK VALUE AT THE END OF THE PERIOD	(24)	<u>1.231.151</u>	

LEASING AND OTHER SIMILAR RIGHTS

Acquisition value at the end of the period

Codes	Period	Preceding period
8194P	xxxxxxxxxxxxxxxx	0

Movements during the period

Acquisitions, including produced fixed assets

8164

Sales and disposals

8174

Transfers from one heading to another

(+)/(-)

8184

Acquisition value at the end of the period

8194

0

Revaluation surpluses at the end of the period

8254P

xxxxxxxxxxxxxxxx

Movements during the period

Recorded

8214

Acquisitions from third parties

8224

Cancelled

8234

Transfers from one heading to another

(+)/(-)

8244

Revaluation surpluses at the end of the period

8254

Amortisations and amounts written down at the end of the period

8324P

xxxxxxxxxxxxxxxx

0

Movements during the period

Recorded

8274

Written back

8284

Acquisitions from third parties

8294

Cancelled owing to sales and disposals

8304

Transferred from one heading to another

(+)/(-)

8314

Amortisations and amounts written down at the end of the period

8324

0

NET BOOK VALUE AT THE END OF THE PERIOD

(25)

0

Of which

Land and buildings

250

Plant, machinery and equipment

251

Furniture and vehicles

252

OTHER TANGIBLE FIXED ASSETS

Acquisition value at the end of the period

Codes	Period	Preceding period
8195P	xxxxxxxxxxxxxxxx	

Movements during the period

Acquisitions, including produced fixed assets

8165

Sales and disposals

8175

Transfers from one heading to another

(+)/(-)

8185

Acquisition value at the end of the period

8195

Revaluation surpluses at the end of the period

8255P

xxxxxxxxxxxxxxxx

Movements during the period

Recorded

8215

Acquisitions from third parties

8225

Cancelled

8235

Transferred from one heading to another

(+)/(-)

8245

Revaluation surpluses at the end of the period

8255

Amortisations and amounts written down at the end of the period

8325P

xxxxxxxxxxxxxxxx

Movements during the period

Recorded

8275

Written back

8285

Acquisitions from third parties

8295

Cancelled owing to sales and disposals

8305

Transferred from one heading to another

(+)/(-)

8315

Amortisations and amounts written down at the end of the period

8325

NET BOOK VALUE AT THE END OF THE PERIOD

(26)

0

	Codes	Period	Preceding period
ASSETS UNDER CONSTRUCTION AND ADVANCE PAYMENTS			
Acquisition value at the end of the period	8196P	xxxxxxxxxxxxxxxx	513.176
Movements during the period			
Acquisitions, including produced fixed assets	8166	1.740.229	
Sales and disposals	8176		
Transfers from one heading to another	(+)/(-) 8186		
Acquisition value at the end of the period	8196	2.253.405	
Revaluation surpluses at the end of the period	8256P	xxxxxxxxxxxxxxxx	
Movements during the period			
Recorded	8216		
Acquisitions from third parties	8226		
Cancelled	8236		
Transferred from one heading to another	(+)/(-) 8246		
Revaluation surpluses at the end of the period	8256		
Amortisations and amounts written down at the end of the period	8326P	xxxxxxxxxxxxxxxx	
Movements during the period			
Recorded	8276		
Written back	8286		
Acquisitions from third parties	8296		
Cancelled owing to sales and disposals	8306		
Transferred from one heading to another	(+)/(-) 8316		
Amortisations and amounts written down at the end of the period	8326		
NET BOOK VALUE AT THE END OF THE PERIOD	(27)	<u>2.253.405</u>	

STATEMENT OF FINANCIAL FIXED ASSETS

	Codes	Period	Preceding period
AFFILIATED COMPANIES - PARTICIPATING INTERESTS AND SHARES			
Acquisition value at the end of the period	8391P	xxxxxxxxxxxxxxxx	168.701.235
Movements during the period			
Acquisitions	8361	50.125.013	
Sales and disposals	8371		
Transfers from one heading to another	(+)(-) 8381		
Acquisition value at the end of the period	8391	218.826.248	
Revaluation surpluses at the end of the period	8451P	xxxxxxxxxxxxxxxx	
Movements during the period			
Recorded	8411		
Acquisitions from third parties	8421		
Cancelled	8431		
Transferred from one heading to another	(+)(-) 8441		
Revaluation surpluses at the end of the period	8451		
Amounts written down at the end of the period	8521P	xxxxxxxxxxxxxxxx	14.058.677
Movements during the period			
Recorded	8471	640.322	
Written back	8481		
Acquisitions from third parties	8491		
Cancelled owing to sales and disposals	8501		
Transferred from one heading to another	(+)(-) 8511		
Amounts written down at the end of the period	8521	14.698.999	
Uncalled amounts at the end of the period	8551P	xxxxxxxxxxxxxxxx	
Movements during the period	(+)(-) 8541		
Uncalled amounts at the end of the period	8551		
NET BOOK VALUE AT THE END OF THE PERIOD	(280)	<u>204.127.249</u>	
AFFILIATED COMPANIES - AMOUNTS RECEIVABLE			
NET BOOK VALUE AT THE END OF THE PERIOD	281P	<u>xxxxxxxxxxxxxxxx</u>	<u>93.208.841</u>
Movements during the period			
Appropriations	8581	1.774.695	
Repayments	8591	40.254.942	
Amounts written down	8601	9.428.593	
Amounts written back	8611		
Exchange differences	(+)(-) 8621		
Other movements	(+)(-) 8631		
NET BOOK VALUE AT THE END OF THE PERIOD	(281)	<u>45.300.001</u>	
ACCUMULATED AMOUNTS WRITTEN DOWN ON AMOUNTS RECEIVABLE AT END OF THE PERIOD	8651	<u>9.428.593</u>	

	Codes	Period	Preceding period
COMPANIES LINKED BY PARTICIPATING INTERESTS - PARTICIPATING INTERESTS AND SHARES			
Acquisition value at the end of the period	8392P	xxxxxxxxxxxxxxxx	1
Movements during the period			
Acquisitions	8362		
Sales and disposals	8372		
Transfers from one heading to another	(+)/(-) 8382		
Acquisition value at the end of the period	8392	1	
Revaluation surpluses at the end of the period	8452P	xxxxxxxxxxxxxxxx	
Movements during the period			
Recorded	8412		
Acquisitions from third parties	8422		
Cancelled	8432		
Transferred from one heading to another	(+)/(-) 8442		
Revaluation surpluses at the end of the period	8452		
Amounts written down at the end of the period	8522P	xxxxxxxxxxxxxxxx	
Movements during the period			
Recorded	8472		
Written back	8482		
Acquisitions from third parties	8492		
Cancelled owing to sales and disposals	8502		
Transferred from one heading to another	(+)/(-) 8512		
Amounts written down at the end of the period	8522		
Uncalled amounts at the end of the period	8552P	xxxxxxxxxxxxxxxx	
Movements during the period	(+)/(-) 8542		
Uncalled amounts at the end of the period	8552		
NET BOOK VALUE AT THE END OF THE PERIOD	(282)	1	
COMPANIES LINKED BY PARTICIPATING INTERESTS - AMOUNTS RECEIVABLE			
NET BOOK VALUE AT THE END OF THE PERIOD	283P	xxxxxxxxxxxxxxxx	
Movements during the period			
Appropriations	8582		
Repayments	8592		
Amounts written down	8602		
Amounts written back	8612		
Exchange differences	(+)/(-) 8622		
Other movements	(+)/(-) 8632		
NET BOOK VALUE AT THE END OF THE PERIOD	(283)		
ACCUMULATED AMOUNTS WRITTEN DOWN ON AMOUNTS RECEIVABLE AT END OF THE PERIOD	8652		

	Codes	Period	Preceding period
OTHER COMPANIES - PARTICIPATING INTERESTS AND SHARES			
Acquisition value at the end of the period	8393P	xxxxxxxxxxxxxxxx	0
Movements during the period			
Acquisitions	8363	13.965.180	
Sales and disposals	8373		
Transfers from one heading to another	(+)/(-) 8383		
Acquisition value at the end of the period	8393	13.965.180	
Revaluation surpluses at the end of the period	8453P	xxxxxxxxxxxxxxxx	
Movements during the period			
Recorded	8413		
Acquisitions from third parties	8423		
Cancelled	8433		
Transferred from one heading to another	(+)/(-) 8443		
Revaluation surpluses at the end of the period	8453		
Amounts written down at the end of the period	8523P	xxxxxxxxxxxxxxxx	0
Movements during the period			
Recorded	8473		
Written back	8483		
Acquisitions from third parties	8493		
Cancelled owing to sales and disposals	8503		
Transferred from one heading to another	(+)/(-) 8513		
Amounts written down at the end of the period	8523	0	
Uncalled amounts at the end of the period	8553P	xxxxxxxxxxxxxxxx	
Movements during the period	(+)/(-) 8543		
Uncalled amounts at the end of the period	8553		
NET BOOK VALUE AT THE END OF THE PERIOD	(284)	<u>13.965.180</u>	
OTHER COMPANIES - AMOUNTS RECEIVABLE			
NET BOOK VALUE AT THE END OF THE PERIOD	285/8P	<u>xxxxxxxxxxxxxxxx</u>	<u>4.066.414</u>
Movements during the period			
Appropriations	8583	1.008.750	
Repayments	8593	68.074	
Amounts written down	8603		
Amounts written back	8613		
Exchange differences	(+)/(-) 8623		
Other movements	(+)/(-) 8633		
NET BOOK VALUE AT THE END OF THE PERIOD	(285/8)	<u>5.007.090</u>	
ACCUMULATED AMOUNTS WRITTEN DOWN ON AMOUNTS RECEIVABLE AT END OF THE PERIOD	8653		

PARTICIPATING INTERESTS INFORMATION**PARTICIPATING INTERESTS AND OTHER RIGHTS IN OTHER COMPANIES**

The following list mentions the companies in which the company holds a participating interest (recorded in headings 280 and 282 of assets), as well as the companies in which the company holds rights (recorded in headings 284 and 51/53 of assets) for an amount of at least 10% of the capital, the equity or a class of shares of the company.

NAME, full address of the REGISTERED OFFICE and, for an entity governed by Belgian law, the COMPANY REGISTRATION NUMBER	Rights held			Data extracted from the most recent annual accounts				
	Nature	Directly		Subsidiaries	Annual accounts as per	Currency code	Equity	Net result
		Number	%				%	(+) or (-) (in units)
Galapagos BV Foreign company Willem Einthovenstraat 13 2342 BH Oegstgeest Netherlands 807938397B01	Registered shares	200	100,00	0,00	31-12-2023	EUR	3.211.184	-2.024.862
Galapagos Biotech Limited Foreign company Salisbury House, Station CB1 2LA Cambridgeshire United Kingdom 203017668	Registered shares	84.700.014	100,00	0,00	31-12-2023	GBP	4.748.401	2.198.252
Galapagos SASU Foreign company Avenue Gaston Roussel 102 93230 Romainville France 27440348480	Registered shares	51.199	100,00	0,00	31-12-2023	EUR	74.691.265	12.333.065
Galapagos GmbH Foreign company Aeschengraben 27 4051 Basel Switzerland CHE388581566	Registered shares	200	100,00	0,00	31-12-2023	CHF	2.394.452	1.916.959
Galapagos Real Estate Belgium Private limited company Generaal De Wittelaan L11 , box A3 2800 Mechelen Belgium 0714.965.620	Registered shares	1.120	100,00	0,00	31-12-2023	EUR	-8.575.421	-8.765.899
Galapagos Biopharma Belgium BV Private limited company Generaal De Wittelaan L11 , box A3 2800 Mechelen Belgium 0727.786.248	Registered shares	500.000	100,00	0,00	31-12-2023	EUR	1.149.553	445.453

PARTICIPATING INTERESTS INFORMATION**PARTICIPATING INTERESTS AND OTHER RIGHTS IN OTHER COMPANIES**

The following list mentions the companies in which the company holds a participating interest (recorded in headings 280 and 282 of assets), as well as the companies in which the company holds rights (recorded in headings 284 and 51/53 of assets) for an amount of at least 10% of the capital, the equity or a class of shares of the company.

NAME, full address of the REGISTERED OFFICE and, for an entity governed by Belgian law, the COMPANY REGISTRATION NUMBER	Rights held			Data extracted from the most recent annual accounts				
	Nature	Directly		Subsidiaries	Annual accounts as per	Currency code	Equity	Net result
		Number	%				%	(+) or (-) (in units)
Galapagos Biopharma Netherlands BV Foreign company Willem Einthovenstraat 13 2342 BH Oestgeest Netherlands NL860020368B	Registered shares	500.000	100,00	0,00	31-12-2023	EUR	932.382	271.695
Galapagos Biopharma Spain S.L.U Foreign company Cuatro Torres - Paseo de la Castellana 28046 Madrid Spain ESB67445429	Registered shares	3.000	100,00	0,00	31-12-2023	EUR	1.910.557	421.685
Galapagos Biopharma Italy S.r.l. Foreign company Via Ceresio 7 20154 Milano Italy 1097290096	Registered shares	50.000	100,00	0,00	31-12-2023	EUR	269.943	252.931
Galapagos Biopharma Germany GmbH Foreign company Luise-Ulrich strasse 8 80636 Munchen Germany DE326847734	Registered shares	25.000	100,00	0,00	31-12-2023	EUR	3.117.463	1.415.625
Galapagos Real Estate Netherlands B.V. Foreign company Willem Einthovenstraat 13 2342 BH Oestgeest Netherlands 860584859B01	Registered shares	10.000.000	100,00	0,00	31-12-2023	EUR	31.217.607	-3.098.918
Galapagos Biopharma Denmark ApS Foreign company Sundkrogsgade , Harbour House 21 2100 Copenhagen Denmark 42447242	Registered shares				31-12-2023	DKK	3.275.222	1.391.584

PARTICIPATING INTERESTS INFORMATION**PARTICIPATING INTERESTS AND OTHER RIGHTS IN OTHER COMPANIES**

The following list mentions the companies in which the company holds a participating interest (recorded in headings 280 and 282 of assets), as well as the companies in which the company holds rights (recorded in headings 284 and 51/53 of assets) for an amount of at least 10% of the capital, the equity or a class of shares of the company.

NAME, full address of the REGISTERED OFFICE and, for an entity governed by Belgian law, the COMPANY REGISTRATION NUMBER	Rights held			Data extracted from the most recent annual accounts				
	Nature	Directly		Subsidiaries	Annual accounts as per	Cur-rency code	Equity	Net result
		Number	%				%	(+) or (-) (in units)
Galapagos Biopharma Sweden AB Foreign company Vasagatan 7 10123 Stockholm Sweden 559311454801	Registered shares	40.000	100,00	0,00	31-12-2023	SEK	5.315.134	2.576.327
Galapagos Biopharma Finland Oy Foreign company Uudenmaankatu 1-5 00120 Helsinki Finland 32201288	Registered shares	25.000	100,00	0,00	31-12-2023	EUR	115.740	24.118
Galapagos Biopharma Ireland Ltd Foreign company Block 3 Harcourt Centre, Harcourt Road D02A339 Dublin Ireland 3791298BH	Registered shares	1	100,00	0,00	31-12-2023	EUR	67.994	39.460
Galapagos Biopharma Norway AS Foreign company Wergelansveien 7 0167 Oslo Norway 927480654	Registered shares	1	100,00	0,00	31-12-2023	NOK	762.776	293.119
Galapagos Biopharma Austria GmbH Foreign company Schottenring 25 1010 Vienna Austria U77339907	Registered shares	30.000	100,00	0,00	31-12-2023	EUR	754.438	319.094
Galapagos US Holding Inc Foreign company North State Street 800 , box 304 19901 Dover, Delaware United States	Registered shares	1	100,00	0,00	31-12-2023	USD	8.395.558	-295.935

PARTICIPATING INTERESTS INFORMATION

PARTICIPATING INTERESTS AND OTHER RIGHTS IN OTHER COMPANIES

The following list mentions the companies in which the company holds a participating interest (recorded in headings 280 and 282 of assets), as well as the companies in which the company holds rights (recorded in headings 284 and 51/53 of assets) for an amount of at least 10% of the capital, the equity or a class of shares of the company.

NAME, full address of the REGISTERED OFFICE and, for an entity governed by Belgian law, the COMPANY REGISTRATION NUMBER	Rights held				Data extracted from the most recent annual accounts			
	Nature	Directly		Subsidiaries	Annual accounts as per	Currency code	Equity	Net result
		Number	%				%	(+) or (-) (in units)
	Aandelen op naam	100	100,00	0,00				

LIST OF COMPANIES FOR WHICH THE COMPANY HAS UNLIMITED LIABILITY IN THE CAPACITY OF UNLIMITED LIABLE PARTNER OR MEMBER

The annual accounts of each company for which the company has unlimited liability, are being enclosed to and published with these annual accounts, unless the second column contains the reason why this is not the case; this mention is made by referring to the applicable code (A,B, C or D) defined below.

The annual accounts of the mentioned company:

- A. are published by the company by filing them at the National Bank of Belgium;
- B. are actually published by the company in a different member country of the European Union, pursuant to article 16 of directive (EU) 2017/1132;
- C. are being inserted by complete or proportional consolidation into the consolidated annual accounts of the company, drawn up, verified and published in accordance with the stipulations of the Belgian Companies and Associations Code concerning the consolidated annual accounts;
- D. concern a limited partnership (société simple/maatschap).

NAME, full address of the REGISTERED OFFICE, LEGAL FORM and, for an entity governed by Belgian law, the COMPANY REGISTRATION NUMBER	Potential code
<p>Galapagos BV Foreign company Willem Einthovenstraat 13 2342 Oestgeest Netherlands</p>	C
<p>Galapagos Biopharma Netherlands B.V. Foreign company Willem Einthovenstraat 13 2342 Oestgeest Netherlands</p>	C
<p>Galapagos Real Estate Netherlands B.V. Foreign company Willem Einthovenstraat 13 2342 Oestgeest Netherlands</p>	C

CURRENT INVESTMENTS AND ACCRUALS AND DEFERRED INCOME

	Codes	Period	Preceding period
CURRENT INVESTMENTS - OTHER INVESTMENTS			
Shares and investments other than fixed income investments			
Shares – Book value increased with the uncalled amount	51		
Shares – Uncalled amount	8681		
Precious metals and works of art	8682		
	8683		
Fixed-income securities			
Fixed income securities issued by credit institutions	52		
	8684		
Term accounts with credit institutions			
With a remaining term or notice	53	1.540.936.652	1.593.596.194
up to one month	8686	95.000.000	55.000.000
between one month and one year	8687	1.445.936.652	1.488.596.194
over one year	8688		50.000.000
Other investments not mentioned above	8689	2.035.493.507	2.042.348.421

ACCRUALS AND DEFERRED INCOME**Allocation of account 490/1 of assets if the amount is significant**

	Period
Deferred charges	10.889.216
Accrued income	14.607.692
Accrued subsidies	43.477

STATEMENT OF CAPITAL AND SHAREHOLDERS' STRUCTURE**STATEMENT OF CAPITAL****Capital**

Issued capital at the end of the period
 Issued capital at the end of the period

Codes	Period	Preceding period
100P	XXXXXXXXXXXXXXXX	356.111.899
(100)	356.444.939	

Modifications during the period

Uitoefening warranten 20/03/2023

Composition of the capital
 Share types

Aandelen zonder nominale waarde

Registered shares

Shares dematerialized

Codes	Period	Number of shares
	333.040	61.560
	356.444.939	65.897.071
8702	XXXXXXXXXXXXXXXX	5.846
8703	XXXXXXXXXXXXXXXX	65.891.225

Unpaid capital

Uncalled capital

Called up capital, unpaid

Shareholders that still need to pay up in full

Codes	Uncalled amount	Called up amount, unpaid
(101)		XXXXXXXXXXXXXXXX
8712	XXXXXXXXXXXXXXXX	

Own shares

Held by the company itself

Amount of capital held

Number of shares

Held by a subsidiary

Amount of capital held

Number of shares

Commitments to issuing shares

Owing to the exercise of conversion rights

Amount of outstanding convertible loans

Amount of capital to be subscribed

Corresponding maximum number of shares to be issued

Owing to the exercise of subscription rights

Number of outstanding subscription rights

Amount of capital to be subscribed

Corresponding maximum number of shares to be issued

Authorised capital not issued

Codes	Period
8721	
8722	
8731	
8732	
8740	
8741	
8742	
8745	11.472.521
8746	62.056.203
8747	11.472.521
8751	16.566.540

Shares issued, non-representing capital

Distribution

Number of shares

Number of voting rights attached thereto

Allocation by shareholder

Number of shares held by the company itself

Number of shares held by its subsidiaries

Codes	Period
8761	
8762	
8771	
8781	

ADDITIONAL NOTES REGARDING CONTRIBUTIONS (INCLUDING CONTRIBUTIONS IN THE FORM OF SERVICES OR KNOW-HOW)

Period

SHAREHOLDERS' STRUCTURE OF THE COMPANY AT YEAR-END CLOSING DATE

As reflected in the notifications received by the company pursuant to article 7:225 of the Belgian Companies and Associations Code, article 14 fourth paragraph of the law of 2 May 2007 on the publication of major holdings and article 5 of the Royal Decree of 21 August 2008 on further rules for certain multilateral trading facilities.

NAME of the person(s) who hold rights of the company, together with the ADDRESS (of the registered office, in the case of a legal person) and the COMPANY REGISTRATION NUMBER, in the case of a company governed by Belgian law	Nature	Rights held		%
		Attached to securities	Not attached to securities	
Gilead Therapeutics A1 Unlimited Company 70 Sir John Rogerson's Quay, Dublin 2, Ireland	Dematerialized shares	16.707.477		25,35%
Van Herk Investments B.V. Lichtenauerlaan 30, 3062 ME Rotterdam, NL	Dematerialized shares	4.635.672		7,03%
EcoR1 Capital LLC 357 Tehema Street, Suite 3, San Francisco, CA 94103, United States of America	Dematerialized shares	6.505.890		9,87%
FMR LLC The Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware, 19801	Dematerialized shares	3.903.804		5,92%
		Total shares		65.897.071,00

PROVISIONS FOR OTHER LIABILITIES AND CHARGES

ALLOCATION OF ACCOUNT 164/5 OF LIABILITIES IF THE AMOUNT IS SIGNIFICANT

Provision Restricted Stock Units
Tax recovery mechanism

Period
10.594.912
3.377.154

STATEMENT OF AMOUNTS PAYABLE AND ACCRUALS AND DEFERRED INCOME (LIABILITIES)

	Codes	Period
BREAKDOWN OF AMOUNTS PAYABLE WITH AN ORIGINAL TERM OF MORE THAN ONE YEAR, ACCORDING TO THEIR RESIDUAL MATURITY		
Current portion of amounts payable after more than one year falling due within one year		
Financial debts	8801	
Subordinated loans	8811	
Unsubordinated debentures	8821	
Leasing and other similar obligations	8831	
Credit institutions	8841	
Other loans	8851	
Trade debts	8861	
Suppliers	8871	
Bills of exchange payable	8881	
Advance payments on contracts in progress	8891	
Other amounts payable	8901	
Total current portion of amounts payable after more than one year falling due within one year	(42)	
Amounts payable with a remaining term of more than one year, yet less than 5 years		
Financial debts	8802	
Subordinated loans	8812	
Unsubordinated debentures	8822	
Leasing and other similar obligations	8832	
Credit institutions	8842	
Other loans	8852	
Trade debts	8862	
Suppliers	8872	
Bills of exchange payable	8882	
Advance payments on contracts in progress	8892	
Other amounts payable	8902	
Total amounts payable with a remaining term of more than one year, yet less than 5 years	8912	
Amounts payable with a remaining term of more than 5 years		
Financial debts	8803	
Subordinated loans	8813	
Unsubordinated debentures	8823	
Leasing and other similar obligations	8833	
Credit institutions	8843	
Other loans	8853	
Trade debts	8863	
Suppliers	8873	
Bills of exchange payable	8883	
Advance payments on contracts in progress	8893	
Other amounts payable	8903	
Amounts payable with a remaining term of more than 5 years	8913	

AMOUNTS PAYABLE GUARANTEED *(included in accounts 17 and 42/48 of liabilities)***Amounts payable guaranteed by the Belgian government agencies**

	Codes	Period
Financial debts	8921	
Subordinated loans	8931	
Unsubordinated debentures	8941	
Leasing and other similar obligations	8951	
Credit institutions	8961	
Other loans	8971	
Trade debts	8981	
Suppliers	8991	
Bills of exchange payable	9001	
Advance payments on contracts in progress	9011	
Remuneration and social security	9021	
Other amounts payable	9051	
Total of the amounts payable guaranteed by the Belgian government agencies	9061	

Amounts payable guaranteed by real securities given or irrevocably promised by the company on its own assets

Financial debts	8922	
Subordinated loans	8932	
Unsubordinated debentures	8942	
Leasing and other similar obligations	8952	
Credit institutions	8962	
Other loans	8972	
Trade debts	8982	
Suppliers	8992	
Bills of exchange payable	9002	
Advance payments on contracts in progress	9012	
Taxes, remuneration and social security	9022	
Taxes	9032	
Remuneration and social security	9042	
Other amounts payable	9052	
Total amounts payable guaranteed by real securities given or irrevocably promised by the company on its own assets	9062	

TAXES, REMUNERATION AND SOCIAL SECURITY**Taxes** *(headings 450/3 and 178/9 of liabilities)*

Outstanding tax debts	9072	
Accruing taxes payable	9073	2.310.567
Estimated taxes payable	450	

Remuneration and social security *(headings 454/9 and 178/9 of liabilities)*

Amounts due to the National Social Security Office	9076	
Other amounts payable in respect of remuneration and social security	9077	21.447.014

ACCRUALS AND DEFERRED INCOME

Allocation of heading 492/3 of liabilities if the amount is significant

Accrued charges
Deferred income
Deferred subsidies
Deferred tax credit

Period
537.523
1.297.596.976
809.861
4.768.426

OPERATING RESULTS**OPERATING INCOME****Net turnover**

Allocation by categories of activity

Research & Development	581.275.559	418.495.174
Royalties	9.465.229	
Sales of trading products	38.158.275	

Allocation by geographical market

US - United States	493.768.671	355.933.790
FR - France	1.412.714	1.061.117
DE - Germany	23.703.679	0
LU - Luxemburg		0
BS - Bahama's	88.171.352	32.218.166
BE - Belgium	2.850.918	17.377.287
NL - The Netherlands	1.427.094	497.512
ES - Spain	1.126.435	513.166
GB - United Kingdom	3.069.118	1.475.413
IE - Ireland	544.095	437.798
IT - Italy	1.806.386	1.246.643
AT - Austria	3.794.280	2.471.940
CH - Switzerland		55.839
Fi - Finland	764.067	264.843
SE - Sweden	3.960.278	2.745.974
No - Norway	2.474.127	2.195.686
DK - Denmark	25.850	

Other operating income

Operating subsidies and compensatory amounts received from public authorities	740	6.618.032	1.804.327
---	-----	-----------	-----------

OPERATING CHARGES**Employees for whom the company submitted a DIMONA declaration or who are recorded in the general personnel register**

Total number at the closing date	9086	367	442
Average number of employees calculated in full-time equivalents	9087	368,6	432,6
Number of actual hours worked	9088	622.373	720.120

Personnel costs

Remuneration and direct social benefits	620	55.931.319	59.050.615
Employers' contribution for social security	621	12.942.717	12.402.668
Employers' premiums for extra statutory insurance	622	2.724.157	2.558.186
Other personnel costs	623	1.957.465	3.760.652
Retirement and survivors' pensions	624		

	Codes	Period	Preceding period
Provisions for pensions and similar obligations			
Appropriations (uses and write-backs)	(+)/(-) 635		
Depreciations			
On stock and contracts in progress			
Recorded	9110		1.239.142
Written back	9111		
On trade debtors			
Recorded	9112		
Written back	9113		
Provisions for liabilities and charges			
Appropriations	9115	4.220.419	866.214
Uses and write-backs	9116		
Other operating charges			
Taxes related to operation	640	3.731.217	4.041.673
Other	641/8	67.053.825	98.107.447
Hired temporary staff and personnel placed at the company's disposal			
Total number at the closing date	9096		
Average number calculated in full-time equivalents	9097	0,7	6,5
Number of actual hours worked	9098	1.440	3.238
Costs to the company	617	34.068	84.787

FINANCIAL RESULTS

	Codes	Period	Preceding period
RECURRING FINANCIAL INCOME			
Other financial income			
Subsidies paid by public authorities, added to the profit and loss account			
Capital subsidies	9125		
Interest subsidies	9126		
Allocation of other financial income			
Exchange differences realized	754	1.620.821	13.265.513
Other			
Other financial gains		22.666	31.623
Unrealized exchange gains		0	89.296.991
RECURRING FINANCIAL CHARGES			
Depreciation of loan issue expenses	6501		
Capitalised interests	6502	4.053.120	2.197.496
Depreciations on current assets			
Recorded	6510		
Written back	6511	9.102.765	
Other financial charges			
Amount of the discount borne by the company, as a result of negotiating amounts receivable	653		125
Provisions of a financial nature			
Appropriations	6560		
Uses and write-backs	6561		
Allocation of other financial costs			
Exchange differences realized	654	0	9.927.654
Results from the conversion of foreign currencies	655		
Other			
Unrealized exchange losses		30.873.435	37.714.315
Bank charges		714.971	615.692
Payment differences		3.497	1.703
Other financial charges		875.195	1.619.153

INCOME AND CHARGES OF EXCEPTIONAL SIZE OR FREQUENCY

	Codes	Period	Preceding period
NON-RECURRING INCOME	76	547.659	19.000
Non-recurring operating income	(76A)	547.659	19.000
Write-back of depreciation and of amounts written off intangible and tangible fixed assets	760		
Write-back of provisions for extraordinary operating liabilities and charges	7620		
Capital profits on disposal of intangible and tangible fixed assets	7630	3.614	19.000
Other non-recurring operating income	764/8	544.045	
Non-recurring financial income	(76B)		0
Write-back of amounts written down financial fixed assets	761		
Write-back of provisions for extraordinary financial liabilities and charges	7621		
Capital profits on disposal of financial fixed assets	7631		
Other non-recurring financial income	769		
NON-RECURRING CHARGES	66	11.106.324	36.854.421
Non-recurring operating charges	(66A)	1.037.409	36.854.421
Non-recurring depreciation of and amounts written off formation expenses, intangible and tangible fixed assets	660	932.662	35.566.302
Provisions for extraordinary operating liabilities and charges: appropriations (uses)	(+)(-) 6620		
Capital losses on disposal of intangible and tangible fixed assets	6630	104.748	288.120
Other non-recurring operating charges	664/7		1.000.000
Non-recurring operating charges carried to assets as restructuring costs	(-) 6690		
Non-recurring financial charges	(66B)	10.068.915	0
Amounts written off financial fixed assets	661	10.068.915	
Provisions for extraordinary financial liabilities and charges - appropriations (uses)	(+)(-) 6621		
Capital losses on disposal of financial fixed assets	6631		
Other non-recurring financial charges	668		
Non-recurring financial charges carried to assets as restructuring costs	(-) 6691		

TAXES

INCOME TAXES

Income taxes on the result of the period

Income taxes paid and withholding taxes due or paid
 Excess of income tax prepayments and withholding taxes paid recorded under assets
 Estimated additional taxes

Income taxes on the result of prior periods

Additional income taxes due or paid
 Additional income taxes estimated or provided for

Major reasons for the differences between pre-tax profit, as it results from the annual accounts, and estimated taxable profit

Non-deductible expenses
 Tax credit
 Excess depreciations
 Exemption regional contributions

Codes	Period
9134	72.259
9135	304.654
9136	304.654
9137	72.259
9138	
9139	
9140	
	5.193.861
	-26.711.807
	-30.400.753
	-538.407

Influence of non-recurring results on income taxes on the result of the period

Period

Sources of deferred taxes

Deferred taxes representing assets
 Accumulated tax losses deductible from future taxable profits
 Other deferred taxes representing assets
 Investment deduction
 Deduction for innovation income
 Excess depreciations
 DBI
 Deferred taxes representing liabilities
 Allocation of deferred taxes representing liabilities

Codes	Period
9141	1.701.941.806
9142	757.947.489
	966.348
	390.310.849
	534.028.071
	18.689.049
9144	

VALUE-ADDED TAXES AND TAXES BORNE BY THIRD PARTIES

Value-added taxes charged

To the company (deductible)
 By the company

Amounts withheld on behalf of third party by way of

Payroll withholding taxes
 Withholding taxes on investment income

Codes	Period	Preceding period
9145	27.244.542	29.346.606
9146	12.736.222	11.975.602
9147	23.134.701	29.561.849
9148		

RIGHTS AND COMMITMENTS NOT REFLECTED IN THE BALANCE SHEET

PERSONAL GUARANTEES PROVIDED OR IRREVOCABLY PROMISED BY THE COMPANY AS SECURITY FOR DEBTS AND COMMITMENTS OF THIRD PARTIES

Of which

Bills of exchange in circulation endorsed by the company

Bills of exchange in circulation drawn or guaranteed by the company

Maximum amount for which other debts or commitments of third parties are guaranteed by the company

REAL GUARANTEES

Real guarantees provided or irrevocably promised by the company on its own assets as security of debts and commitments of the company

Mortgages

Book value of the immovable properties mortgaged

Amount of registration

For irrevocable mortgage mandates, the amount for which the agent can take registration

Pledging of goodwill

Maximum amount up to which the debt is secured and which is the subject of registration

For irrevocable mandates to pledge goodwill, the amount for which the agent can take the inscription

Pledging of other assets or irrevocable mandates to pledge other assets

Book value of the immovable properties mortgaged

Maximum amount up to which the debt is secured

Guarantees provided or irrevocably promised on future assets

Amount of assets in question

Maximum amount up to which the debt is secured

Vendor's privilege

Book value of sold goods

Amount of the unpaid price

Codes	Period
9149	<u>4.998.336</u>
9150	
9151	
9153	4.998.336
91611	
91621	
91631	
91711	
91721	
91811	
91821	
91911	
91921	
92011	
92021	

SETTLEMENT REGARDING THE COMPLEMENTARY RETIREMENT OR SURVIVORS' PENSION FOR PERSONNEL AND BOARD MEMBERS

Brief description

Galapagos NV has a group insurance and guaranteed income insurance in favor of their personnel and directors. Galapagos NV carries all costs related to these insurances. The amount of the premium contribution was 2.757K EUR in 2023.

Measures taken to cover the related charges

PENSIONS FUNDED BY THE COMPANY ITSELF

Estimated amount of the commitments resulting from past services

Methods of estimation

Galapagos NV has a group insurance and guaranteed income insurance in favor of their personnel and directors. Galapagos NV carries all costs related to these insurances. The amount of the premium contribution was 2.757K EUR in 2023.

Code	Period
9220	

NATURE AND FINANCIAL IMPACT OF SIGNIFICANT EVENTS AFTER THE CLOSING DATE not reflected in the balance sheet or income statement

On January 3, 2024, a strategic collaboration and licensing agreement was signed with BridGene Biosciences. BridGene has received an upfront payment of USD 27 million.

On January 31, 2024, the transaction regarding the Jyseleca activities was successfully completed with Alfasigma. For this Alfasigma made an upfront payment of EUR 50 million, plus EUR 13.2 million for the cash position and net working capital.

On January 31, 2024, Galapagos NV participated in a Series C financing round of Frontier Medicines for an amount of USD 40 million.

Period
24.434.389
63.200.000
36.199.095

COMMITMENTS TO PURCHASE OR SALE AVAILABLE TO THE COMPANY AS ISSUER OF OPTIONS FOR SALE OR PURCHASE

Period

NATURE, COMMERCIAL OBJECTIVE AND FINANCIAL CONSEQUENCES OF TRANSACTIONS NOT REFLECTED IN THE BALANCE SHEET

If the risks and benefits resulting from such transactions are of any meaning and if publishing such risks and benefits is necessary to appreciate the financial situation of the company

Period

OTHER RIGHTS AND COMMITMENTS NOT REFLECTED IN THE BALANCE SHEET (including those that cannot be calculated)

Period

**RELATIONSHIPS WITH AFFILIATED COMPANIES, ASSOCIATED COMPANIES AND OTHER COMPANIES
LINKED BY PARTICIPATING INTERESTS**

	Codes	Period	Preceding period
AFFILIATED COMPANIES			
Financial fixed assets	(280/1)	249.427.250	247.851.399
Participating interests	(280)	204.127.249	154.642.558
Subordinated amounts receivable	9271	45.300.001	93.208.841
Other amounts receivable	9281		
Amounts receivable	9291	43.820.046	64.503.786
Over one year	9301		
Within one year	9311	43.820.046	64.503.786
Current investments	9321		
Shares	9331		
Amounts receivable	9341		
Amounts payable	9351	48.868.651	230.595.113
Over one year	9361		
Within one year	9371	48.868.651	230.595.113
Personal and real guarantees			
Provided or irrevocably promised by the company as security for debts or commitments of affiliated companies	9381	4.162.896	1.950.737
Provided or irrevocably promised by affiliated companies as security for debts or commitments of the company	9391		
Other significant financial commitments	9401		
Financial results			
Income from financial fixed assets	9421	109.515.173	10.500.000
Income from current assets	9431	7.591.058	
Other financial income	9441		3.591.036
Debt charges	9461	3.019.431	
Other financial charges	9471		
Disposal of fixed assets			
Capital profits realised	9481		
Capital losses realised	9491		

RELATIONSHIPS WITH AFFILIATED COMPANIES, ASSOCIATED COMPANIES AND OTHER COMPANIES LINKED BY PARTICIPATING INTERESTS

	Codes	Period	Preceding period
ASSOCIATED COMPANIES			
Financial fixed assets	9253		
Participating interests	9263		
Subordinated amounts receivable	9273		
Other amounts receivable	9283		
Amounts receivable	9293		
Over one year	9303		
Within one year	9313		
Amounts payable	9353		
Over one year	9363		
Within one year	9373		
Personal and real guarantees			
Provided or irrevocably promised by the company as security for debts or commitments of affiliated companies	9383		
Provided or irrevocably promised by affiliated companies as security for debts or commitments of the company	9393		
Other significant financial commitments	9403		
COMPANIES LINKED BY PARTICIPATING INTERESTS			
Financial fixed assets	9252	1	1
Participating interests	9262	1	1
Subordinated amounts receivable	9272		
Other amounts receivable	9282		
Amounts receivable	9292		
Over one year	9302		
Within one year	9312		
Amounts payable	9352		
Over one year	9362		
Within one year	9372		

RELATIONSHIPS WITH AFFILIATED COMPANIES, ASSOCIATED COMPANIES AND OTHER COMPANIES LINKED BY PARTICIPATING INTERESTS

TRANSACTIONS WITH AFFILIATED PARTIES BEYOND NORMAL MARKET CONDITIONS

Mention of these transactions if they are significant, including the amount of the transactions, the nature of the link, and all information about the transactions that should be necessary to get a better understanding of the financial situation of the company

Due to the absence of legal criteria that allow transactions with affiliated parties beyond normal market conditions to be enumerated, no transactions were included in F-cap 6.15.

Period

FINANCIAL RELATIONSHIPS WITH

DIRECTORS AND MANAGERS, INDIVIDUALS OR LEGAL PERSONS WHO CONTROL THE COMPANY DIRECTLY OR INDIRECTLY WITHOUT BEING ASSOCIATED THEREWITH, OR OTHER COMPANIES CONTROLLED DIRECTLY OR INDIRECTLY BY THESE PERSONS

Amounts receivable from these persons

Principal conditions regarding amounts receivable, rate of interest, duration, any amounts repaid, cancelled or written off

Guarantees provided in their favour

Other significant commitments undertaken in their favour

Amount of direct and indirect remunerations and pensions, reflected in the income statement, as long as this disclosure does not concern exclusively or mainly, the situation of a single identifiable person

To directors and managers

To former directors and former managers

Codes	Period
9500	
9501	
9502	
9503	748.993
9504	

THE AUDITOR(S) AND THE PERSONS WHOM HE (THEY) IS (ARE) COLLABORATING WITH

Auditors' fees

Fees for exceptional services or special assignments executed within the company by the auditor

Other audit assignments

Tax consultancy assignments

Other assignments beyond the audit

Fees for exceptional services or special assignments executed within the company by people the auditor(s) is (are collaborating with

Other audit assignments

Tax consultancy assignments

Other assignments beyond the audit

Codes	Period
9505	1.043.258
95061	20.209
95062	
95063	6.605
95081	
95082	67.964
95083	

Mentions related to article 3:64, § 2 and § 4 of the Belgian Companies and Associations Code

DECLARATION WITH REGARD TO THE CONSOLIDATED ANNUAL ACCOUNTS**INFORMATION TO DISCLOSE BY EACH COMPANY GOVERNED BY THE BELGIAN COMPANIES AND ASSOCIATIONS CODE ON THE CONSOLIDATED ANNUAL ACCOUNTS**

The company has prepared and published consolidated annual accounts and a consolidated annual report*

~~The company has not prepared consolidated annual accounts and a consolidated annual report, because of an exemption for the following reason(s)*~~

~~The company and its subsidiaries exceed, on a consolidated basis, not more than one of the criteria mentioned in article 1:26 of the Belgian Companies and Associations Code*~~

~~The company only has subsidiaries that, considering the evaluation of the consolidated capital, the consolidated financial position or the consolidated result, individually or together, are of negligible interestError! Bookmark not defined. (article 3:23 of the Belgian Companies and Associations Code)~~

~~The company itself is a subsidiary of a parent company that prepares and publishes consolidated annual accounts, in which the annual accounts are integrated by consolidation*~~

Name, full address of the registered office and, if it concerns companies under Belgian law, the company registration number of the parent company(ies) and the indication if this (these) parent company(ies) prepares (prepare) and publishes (publish) consolidated annual accounts, in which the annual accounts are included by means of consolidation**:

If the parent company(ies) is (are) (a) company(ies) governed by foreign law, the location where the abovementioned annual accounts are available**:

* Strike out what does not apply.

** Where the annual accounts of the company are consolidated at different levels, the information should be given, on the one hand at the highest and on the other at the lowest level of companies of which the company is a subsidiary and for which consolidated accounts are prepared and published.

FINANCIAL RELATIONSHIPS OF THE GROUP THE COMPANY IS IN CHARGE OF IN BELGIUM WITH THE AUDITOR(S) AND THE PERSONS WITH WHOM HE (THEY) IS (ARE) LINKED

Mentions related to article 3:65, § 4 and § 5 of the Belgian Companies and Associations Code

Fees to auditors according to the mandate at the group level led by the company publishing the information

Fees for exceptional services or special missions executed by the auditor(s) at this group

Other audit assignments

Tax consultancy assignments

Other assignments beyond the audit

Fees to people auditors are linked to according to the mandate at the group level led by the company publishing the information

Fees for exceptional services or special assignments executed at this group by people the auditor(s) is (are) linked to

Other audit assignments

Tax consultancy assignments

Other assignments beyond the audit

Codes	Period
9507	1.124.038
95071	20.209
95072	
95073	6.605
9509	
95091	
95092	67.964
95093	

Mentions related to article 3:64, § 2 and § 4 of the Belgian Companies and Associations Code

VALUATION RULES

The valuation rules were prepared in accordance with the provisions of Chapter II of the Royal Decree of April 29, 2019 related to corporate financial statements and are valid for evaluating all assets, receivables, payables and obligations of the company.

Any changes will be submitted in advance to the Board of Directors for approval.

The current rules have been established and the evaluation rules are being carried in view of the continuation of the company.

Summary of Valuation Rules:

1. Fixed assets

(a) Intangible assets

The company invests in research and development projects. Research and development expenses are, as of fiscal year 2010, recorded on the assets only to the extent that their cost does not exceed a prudent estimate of their value in use or their future return for the company and amortized over a 3-year period through fiscal year 2015. As from fiscal year 2016 research and development costs that do not qualify as part of a development phase are recorded on the assets and fully amortized in the same fiscal year (according to CBN Opinions 2016/16 and 2016/27).

Research and development in progress acquired through licensing agreements, business combinations, collaboration agreements or separate acquisitions are recognized as intangible assets if they are separately identifiable, controlled by us and can generate economic benefit. Since there is a consideration that for separately acquired research and development assets the probability criterion is met, upfront and success payments to third parties for products or drug candidates for which approval has not yet been received have been recognized as intangible assets. We consider these intangible fixed assets not yet available for use until the underlying asset is approved and commercially launched.

As from approval for commercialization of the underlying asset, depreciation is recorded and the asset will be depreciated over its useful life.

Licenses, patents and know-how are amortized on a straight-line basis over the useful life (usually between 5 and 20 years). Other intangible assets, including acquired intellectual property, are recorded at acquisition cost. These assets are depreciated on a straight-line basis over their estimated useful lives as soon as they are ready for their intended use. They are included in the assets to the extent that their net book value does not exceed a prudent estimate of their value in use or their future returns for the company.

(b) Tangible fixed assets

Property, plant and equipment are recorded at cost. Depreciation is on a straight-line basis, taking into account the economic life of the assets.

- Lab material: 5-10 years
- IT hardware and software: 3-5 years
- Furniture and rolling stock: 5-10 years

2. Trade receivables

Trade receivables are recorded at face value. Foreign currency receivables are translated at the exchange rate valid at the balance sheet date. Exchange differences are recognized in the income statement.

When collection becomes doubtful, a provision is made for doubtful debtors.

3. Stocks

Raw materials, auxiliary materials and trade goods are valued at acquisition cost.

Work in progress and finished goods are valued at cost.

Cost includes, in addition to direct production and material costs, a proportionate share of depreciation and amortization of assets that were used in the production process used.

Inventories are valued using the FIFO method. If the acquisition cost or cost exceeds the net realizable value, valuation at the lower net realizable value is applied. Net realizable value is equal to the estimated normal sales price, less estimated completion costs and estimated costs required to make the sale.

4. Cash investments and liquid assets

Deposits with financial institutions are valued at nominal value. Securities are valued at acquisition cost.

Additional costs are immediately charged to earnings. Write-downs are recorded if the realization value at the balance sheet date is less than the amount previously recorded.

Foreign currency balances are translated at the exchange rate valid at the balance sheet date. Exchange differences are recorded in the income statement.

5. Provisions for other risks and costs.

This included this year's provisions for restricted stock units following the 2018/16 CBN opinion and this reasoning was upheld for the deferred management bonus.

6. Revenue

Revenue to date consists primarily of success payments, license fees, and prepayments obtained from collaboration agreements. The Company also generates revenues from various research and development incentives and grants.

Cooperation agreements with the Company's commercial partners for activities related to research and development generally include non-refundable prepayments received; success payments, whose receipt depends on the achievement of certain clinical, regulatory or commercial milestones; license fees and royalties on selling.

In case of revenue recognition staggered over time, the unrecognized portion is recorded as revenue carried forward.

The revenue recognition policy can be summarized as follows:

(a) Prepayments received

Non-refundable prepayments received in connection with cooperative research agreements and development are spread and recognized over the relevant and desired period of the company's performance commitment. Payments and company involvement are contractually defined by phase. At the outset, Management makes a estimate of the duration of the company's involvement, as well as the costs related to the project. Prepayments are recognized over the expected period of engagement, either on a straight-line basis or based on costs incurred in the framework of the project if these costs can be reliably estimated. Periodically, the Company reviews the estimated time and

VALUATION RULES

cost for the project and adjusts the period over which revenue is spread.

(b) Success payments

A success payment is included in the transaction price only when there is a substantial likelihood that a material reversal of cumulative recognized revenue will not occur.

Success payments that are not irrevocable, substantial or proportionate, are recognized as revenue to be carried forward. Revenue from these activities can vary greatly from period to period due to the timing of the success payment.

(c) Licenses

Revenues arising from licenses limited in time are spread over the period covered by the license, which increases the obligation of the license reflects over that term, to update the content and ensure continuous updating.

Proceeds from perpetual licenses are recognized immediately upon sale to the extent that there are no further obligations.

(d) Royalty agreements

Royalty income is recognized when the Company can estimate the amount with reasonable certainty and a reasonable assurance of collectability exists. As a result, the company is generally going to recognize royalties in the period that the licensee reported the royalties to the company through royalty reports, i.e., the royalty income is normally recognized only retrospectively, after the period in which sales by the licensee have occurred. Under this accounting rule, revenues arising from royalties included in the reporting of the company are not based on an estimate by the company but are typically reported in the same period as the obtained payment from the licensee.

(e) Grants and R&D support measures.

Because the company participates extensively in research and development activities, the company also benefits from multiple subsidies and R&D support measures from certain government agencies. These subsidies and R&D support measures are generally used to partially reimburse approved research and development costs. They are therefore credited to the earnings, under other income (excluding tax credit for research and development costs), when the relevant expenditures have been made and reasonable certainty exists about the subsidies (to be) received and R&D support measures.

f) Proceeds recognition from collaboration with Gilead to develop filgotinib

This is included in the result due to the termination of activities for a value of EUR 348.728.994.

- Identification of the contract

Despite the recent addition to the collaboration agreement with Gilead for the development of filgotinib, management assessed that all activities remain beneficial

for the development of filgotinib, of which Gilead still retains the rights outside Europe. All contract changes were analyzed as we believe that Gilead should still be a customer

to be considered as. This is also supported by the fact that we concluded that there is only one results commitment remains related to filgotinib.

- Identification of the result obligation

The recent changes to the collaboration agreement with Gilead did not give rise to new results obligations. There was only an adjustment in the scope and price of the existing filgotinib

result obligation, which was only partially fulfilled at the time of the change.

- Allocation of the total transaction price

We assessed that the contract change only affects the scope of the filgotinib performance commitment and that the change in both fixed and variable compensation reflects the adjusted

stand-alone sales price of the remaining activities of this result obligation. If we had assessed that the higher reimbursement was not or only partially related to the filgotinib

result obligation, then the compensation might have been allocated to other result obligations in the contract, leading to a change in the moment of revenue recognition.

The denominator used in the percentage of completion calculation reflects our best estimate of our total costs required to meet the filgotinib performance commitment. These costs were

estimated taking into account management's best estimate of the design and duration of ongoing and planned clinical studies and the timing of the closing of the transaction with Alfasigma.

As a result of this transaction, the agreement with Gilead regarding filgotinib will be transferred to Alfasigma and our performance obligation will be terminated. Reflect the remaining costs as of December 31, 2023

mainly the costs we expect to incur for the transfer to Alfasigma.

The increase in revenue is mainly the result of higher recognition of revenue from upfront payments. This increase is explained by a substantial decrease in our estimated remaining cost to complete the development of filgotinib as a result of the recent sale of all our Jyseleca® activities to Alfasigma including the transfer of the remaining development performance obligation after the closing of the transaction. This led to a significant increase in the percentage of completion of our result commitment and a significant positive catch-up effect in our revenues.

7. Continuity

To date, we have incurred significant operating losses, which is reflected in the balance sheet. However, we believe that our existing short-term financial investments, cash and cash equivalents at December 31, 2023 will enable us to fund our operating costs and capital expenditures for at least the next 12 months. The Board of Directors is also of the opinion that additional funding—if needed—can be obtained. Taking this into account, as well as the potential developments in our drug discovery and development activities, the Board of Directors believes that they can present the financial statements on a going concern basis. Although our short-term financial investments, cash and cash equivalents are sufficiently high for at least the next 12 months, the Board of Directors points out that if R&D activities go well, we will seek additional funding to support the ongoing development of our products or to support other business opportunities.

OTHER INFORMATION TO DISCLOSE

A comfort letter was provided to Galapagos Real Estate Belgium B.V.

SOCIAL BALANCE SHEET

Numbers of the joint industrial committees competent for the company: 207

STATEMENT OF THE PERSONS EMPLOYED**EMPLOYEES FOR WHOM THE COMPANY SUBMITTED A DIMONA DECLARATION OR WHO ARE RECORDED IN THE GENERAL PERSONNEL REGISTER****During the period****Average number of employees**

	Codes	Total	1. Men	2. Women
Full-time	1001	316,9	136,8	180,1
Part-time	1002	63,0	11,5	51,5
Total in full-time equivalents (FTE)	1003	368,6	146,2	222,4

Number of actual hours worked

Full-time	1011	539.184	239.584	299.600
Part-time	1012	83.189	15.665	67.524
Total	1013	622.373	255.249	367.124

Personnel costs

Full-time	1021	63.890.106	31.198.026	32.692.080
Part-time	1022	9.665.552	2.190.556	7.474.996
Total	1023	73.555.658	33.388.582	40.167.076

Benefits in addition to wages

	Codes	Total	1. Men	2. Women
	1033			

During the preceding period

	Codes	P. Total	1P. Men	2P. Women
Average number of employees in FTE	1003	432,6	176,6	256,0
Number of actual hours worked	1013	720.120	297.566	422.554
Personnel costs	1023	77.772.120	36.721.873	41.050.247
Benefits in addition to wages	1033	567.933	232.742	335.192

EMPLOYEES FOR WHOM THE COMPANY SUBMITTED A DIMONA DECLARATION OR WHO ARE RECORDED IN THE GENERAL PERSONNEL REGISTER (continuation)

	Codes	1. Full-time	2. Part-time	3. Total in full-time equivalents
At the closing date of the period				
Number of employees	105	312	55	357,2
By nature of the employment contract				
Contract for an indefinite period	110	312	55	357,2
Contract for a definite period	111			
Contract for the execution of a specifically assigned work	112			
Replacement contract	113			
According to gender and study level				
Men	120	137	7	142,7
primary education	1200	5		5,0
secondary education	1201	9		9,0
higher non-university education	1202	18	2	19,7
university education	1203	105	5	109,0
Women	121	175	48	214,5
primary education	1210	5		5,0
secondary education	1211	3	2	4,6
higher non-university education	1212	40	16	53,0
university education	1213	127	30	151,9
By professional category				
Management staff	130			
Salaried employees	134	312	55	357,2
Hourly employees	132			
Other	133			

HIRED TEMPORARY STAFF AND PERSONNEL PLACED AT THE DISPOSAL OF THE COMPANY

	Codes	1. Hired temporary staff	2. Hired temporary staff and personnel placed at the company's disposal
During the period			
Average number of persons employed	150	0,7	
Number of actual hours worked	151	1.440	
Costs to the company	152	34.068	

LIST OF PERSONNEL MOVEMENTS DURING THE PERIOD**ENTRIES**

Number of employees for whom the company submitted a DIMONA declaration or who have been recorded in the general personnel register during the period

By nature of the employment contract

Contract for an indefinite period

Contract for a definite period

Contract for the execution of a specifically assigned work

Replacement contract

Codes	1. Full-time	2. Part-time	3. Total in full-time equivalents
205	58		58,0
210	58		58,0
211			
212			
213			

DEPARTURES

Number of employees whose contract-termination date has been included in the DIMONA declaration or in the general personnel register during the period

By nature of the employment contract

Contract for an indefinite period

Contract for a definite period

Contract for the execution of a specifically assigned work

Replacement contract

By reason of termination of contract

Retirement

Unemployment with extra allowance from enterprise

Dismissal

Other reason

Of which: the number of persons who continue to render services to the company at least half-time on a self-employment basis

Codes	1. Full-time	2. Part-time	3. Total in full-time equivalents
305	111	22	128,8
310	111	22	128,8
311			
312			
313			
340			
341			
342	74	17	87,7
343	37	5	41,1
350			

INFORMATION ON TRAINING PROVIDED TO EMPLOYEES DURING THE PERIOD

Total of initiatives of formal professional training at the expense of the employer

Number of employees involved
 Number of actual training hours
 Net costs for the company
 of which gross costs directly linked to training
 of which contributions paid and payments to collective funds
 of which grants and other financial advantages received (to deduct)

Total of initiatives of less formal or informal professional training at the expense of the employer

Number of employees involved
 Number of actual training hours
 Net costs for the company

Total of initial initiatives of professional training at the expense of the employer

Number of employees involved
 Number of actual training hours
 Net costs for the company

Codes	Men	Codes	Women
5801		5811	
5802		5812	
5803		5813	
58031		58131	
58032		58132	
58033		58133	
5821	181	5831	277
5822	3.522	5832	5.758
5823	960.504	5833	1.465.063
5841		5851	
5842		5852	
5843		5853	